FDA Approves AbbVie's JUVMO, First Selective D1/D5 Agonist for Parkinson's
ABBV sits 39% above its 52-week low of $190.75.
Summary
The FDA approved AbbVie's JUVMO (tavapadon) for adults with Parkinson's disease, making it the first selective D1/D5 receptor agonist in the class. Phase 3 TEMPO data showed significant improvements in motor symptoms and daily functioning, with 93% of patients on JUVMO plus levodopa not needing a dose increase at 85 weeks. AbbVie expects U.S. launch in October 2026. This approval adds a differentiated neurology asset to AbbVie's portfolio, addressing a large market with limited innovation. Watch for launch uptake and pricing details in the coming months.
At the time of this announcement, ABBV was trading at $264.85 on NYSE in the Life Sciences sector, with a market capitalization of approximately $467.1B. The 52-week trading range was $190.75 to $269.39. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: PR Newswire.